
Biocept Investor Relations Material
Latest events

Status Update
Biocept
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Biocept Inc
Access all reports
Biocept, Inc., is an early stage molecular oncology diagnostic company developing and commercializing proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Biocept's multi-targeted tests will provide oncologists and their patients with valuable information that may affect the course of treatment decision making in non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer (CRC), melanoma and other solid tumors. The company's initial efforts are focused on CS-36, a test to detect 31 NSCLC mutations, eight PI3K pathway mutations and an EGFR mutation in circulating tumor cells from patients' blood. Biocept is also pursuing additional indications for use of its CTC assay for detecting malignant circulating tumor cells. The company is based in San Diego, California.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
BIOC
Country
🇺🇸 United States